Four-Drug attack on stubborn blood cancer
NCT ID NCT07418190
Summary
This study is testing a combination of four medications (zanubrutinib, rituximab, lenalidomide, and tislelizumab) for adults with follicular lymphoma that has come back or hasn't responded to at least two prior treatments. The goal is to see if this drug combo can shrink tumors and keep the cancer under control for longer. After an initial 6-cycle treatment, patients who respond will continue on a two-drug maintenance therapy for up to a year to try to delay the cancer's return.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.